Liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients

Journal of Antimicrobial Chemotherapy

Volumn 49, Issue SUPL. S1, 2002, Pages 81-86

  Cagnoni, Pablo J ^a,b  

^a UNIVERSITY OF COLORADO CANCER CENTER   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; DIPHENHYDRAMINE; FLUCONAZOLE; HYDROCORTISONE; PARACETAMOL; PETHIDINE;

ADULT; ALLOTRANSPLANTATION; ARTICLE; BONE MARROW TRANSPLANTATION; CHILL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DATA ANALYSIS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG COST; DRUG EFFICACY; DRUG INFUSION; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEMALE; FEVER; HOSPITAL BILLING; HOSPITAL COST; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYCOSIS; NEPHROTOXICITY; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SENSITIVITY ANALYSIS; STATISTICAL ANALYSIS;

EID: 0036177170     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/49.suppl_1.81     Document Type: Article

References (4)

1. Systemically administered antifungal agents. A review of their clinical pharmacology and therapeutic applications
2. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia
3. A randomized, double-blind comparative trial evaluating the safety of amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia
4. Pharmacoeconomic analysis of liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients